特定益生菌或可缓解溃疡性结肠炎(综述)
创作:szx 审核:szx 2019年03月10日
  • 共纳入12项RCT研究,共计886名溃疡性结肠炎(UC)患者进行荟萃分析,评估益生菌对UC的影响;
  • 在9项RCT(602名活动性UC患者)中,相比于对照组,益生菌对患者无显著缓解效果;
  • 亚组分析中,益生菌可显著降低活动性UC患者的UC疾病活动指数(UCDAI)及DAI,而含有双歧杆菌的益生菌可显著缓解活动性UC患者的疾病;
  • 在4项RCT(313名非活动性UC患者)中,益生菌对患者无显著缓解效果;
  • 与美沙拉嗪,益生菌的维持缓解效果无显著差异。
主编推荐语
szx
《Nutrients》上发表的一项荟萃分析,发现对于活动性溃疡性结肠炎(UC)患者,益生菌可显著降低患者的疾病活动指数,而含有双歧杆菌的益生菌可显著缓解疾病。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!
图片
Nutrients [IF:4.546]

The Efficacy of Probiotics, Prebiotic Inulin-Type Fructans, and Synbiotics in Human Ulcerative Colitis: A Systematic Review and Meta-Analysis

益生菌、菊粉型果聚糖益生元以及合生制剂对溃疡性结肠炎的作用:一项系统综述和荟萃分析

10.3390/nu11020293

2019-01-30, Review

Abstract & Authors:展开

Abstract:收起
Studies of probiotics, fructan-type prebiotics, and synbiotics in patients with ulcerative colitis (UC) show significant heterogeneity in methodology and results. Here, we study the efficacy of such interventions and the reasons for the heterogeneity of their results. Eligible random controlled trials were collected from the PUBMED and SCOPUS databases. A total of 18 placebo-controlled and active treatment-controlled (i.e., mesalazine) studies were selected with a Jadad score ≥ 3, including 1491 patients with UC. Data for prebiotics and synbiotics were sparse and consequently these studies were excluded from the meta-analysis. The UC remission efficacy of probiotics was measured in terms of relative risk (RR) and odds ratio (OR). Significant effects were observed in patients with active UC whenever probiotics containing bifidobacteria were used, or when adopting the US Food and Drug Administration (FDA)-recommended scales (UC Disease Activity Index and Disease Activity Index). By the FDA recommended scales, the RR was 1.55 (CI95%: 1.13⁻2.15, -value = 0.007, ² = 29%); for bifidobacteria-containing probiotics, the RR was 1.73 (CI95%: 1.23⁻2.43, -value = 0.002, ² = 35%). No significant effects were observed on the maintenance of remission for placebo-controlled or mesalazine-controlled studies. We conclude that a validated scale is necessary to determine the state of patients with UC. However, probiotics containing bifidobacteria are promising for the treatment of active UC.

First Authors:
Erola Astó

Correspondence Authors:
Andreu Farran-Codina

All Authors:
Erola Astó,Iago Méndez,Sergi Audivert,Andreu Farran-Codina,Jordi Espadaler

评论